US 6,184,222 B2Granted

Treatment of conduct disorder

AssigneeEli Lilly and Company

InventorJohn Harrison Heiligenstein

Life of this patent

Estimating the term…

Abstract

Norepinephrine reuptake inhibitors are used to treat conduct disorder.

Claims15

Dependent claims

A method of treating conduct disorder comprising administration to a patient in need of such treatment an effective amount of a norepinephrine reuptake inhibitor selective for norepinephrine over other neurotransmitters.

Dependencies are inferred from the claim text.

Facts

Application: 09/156,285Filed 17 Sep 1998 · us provisional application
Priority: 23 Sep 1997
Granted: 6 Feb 2001
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/135
Amines: having aromatic rings , e.g. ketamine, nortriptyline
A61K 31/5375
Having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines: 1,4-Oxazines, e.g. morpholine

Family

Application60/059,628Us provisional application · filed 23 Sep 1997
US 6,184,222 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results